Table 2. ReaScan TBEa overall performance on serum samples prior found tick-borne encephalitis virus IgM positive or negativeb (n = 313 samples).
| Result description | Country (ReaScan TBEa IgM kit lot used) |
Total | ||||
|---|---|---|---|---|---|---|
| Estonia (QE27/1) |
Finland (RA12/1) |
Slovenia (QE27/1 and QB27/1) |
Sweden (QE27/1) |
The Netherlands (SH16/1) |
||
| TBEV IgM negativec | 0 | 100 | 11 | 30 | 0 | 141 |
| ReaScan negative | 0 | 97 | 11 | 30 | 0 | 138 |
| ReaScan equivocal | 0 | 2 | 0 | 0 | 0 | 2 |
| ReaScan positive | 0 | 1 | 0 | 0 | 0 | 1 |
| TBEV IgM positived | 47 | 55 | 8 | 50 | 12 | 172 |
| ReaScan negative | 0 | 0 | 0 | 0 | 0 | 0 |
| ReaScan equivocal | 1 | 0 | 0 | 0 | 0 | 1 |
| ReaScan positive | 46 | 55 | 8 | 50 | 12 | 171 |
TBEV: tick-borne encephalitis virus.
a ReaScan TBE IgM rapid test (Reagena, Toivala, Finland).
b In this table the TBEV IgM negative samples were not from patients known to have vaccinations, or infections other than with TBEV, that might cause diagnostic problems such as serological cross-reactions.
c In this row, samples which tested TBEV IgM negative through another method than ReaScan TBE are shown.
d In this row, samples which tested TBEV IgM positive through another method than ReaScan TBE are shown.